Warning: The NCBI web site requires JavaScript to function. more...
Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer.
Nolen BM, Marks JR, Ta'san S, Rand A, Luong TM, Wang Y, Blackwell K, Lokshin AE.
Breast Cancer Res. 2008;10(3):R45. Epub 2008 May 12.
Related citations
Neoadjuvant treatment with paclitaxel and epirubicin in invasive breast cancer: a phase II study.
Sarid D, Ron IG, Sperber F, Stadler Y, Kahan P, Kovner F, Ben-Yosef R, Marmor S, Grinberg Y, Maimon N, Weinstein J, Yaal-Hahoshen N.
Clin Drug Investig. 2006;26(12):691-701.
Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer.
Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW, Moon WK, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.
BMC Cancer. 2007 Nov 1;7:203.
Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma.
Pusztai L, Gregory BW, Baggerly KA, Peng B, Koomen J, Kuerer HM, Esteva FJ, Symmans WF, Wagner P, Hortobagyi GN, Laronga C, Semmes OJ, Wright GL Jr, Drake RR, Vlahou A.
Cancer. 2004 May 1;100(9):1814-22.
Neoadjuvant gemcitabine therapy for breast cancer.
Sánchez-Rovira P, Jaén A, Dueñas R, Porras I, Martínez E, Medina B, Mohedano N, Fernández M, Lozano A.
Clin Breast Cancer. 2002 May;3 Suppl 1:39-44. Review.
[Response rates following neoadjuvant chemotherapy and breast preserving treatment in patients with locally advanced breast cancer].
Maráz R, Boross G, Svébis M, Gyánti R, Vizhányó R, Hajnal L, Markó L, Szucs M, Ambrózay E, Lorincz M.
Magy Seb. 2005 Aug;58(4):225-32. Hungarian.
DCE-MRI parameters have potential to predict response of locally advanced breast cancer patients to neoadjuvant chemotherapy and hyperthermia: a pilot study.
Craciunescu OI, Blackwell KL, Jones EL, Macfall JR, Yu D, Vujaskovic Z, Wong TZ, Liotcheva V, Rosen EL, Prosnitz LR, Samulski TV, Dewhirst MW.
Int J Hyperthermia. 2009;25(6):405-15.
Breast cancer and neoadjuvant therapy: any predictive marker?
Vyzula R, Dusek L, Zaloudík J, Demlová R, Klimes D, Selvekerová S.
Neoplasma. 2004;51(6):471-80.
Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer.
Lee J, Im YH, Lee SH, Cho EY, Choi YL, Ko YH, Kim JH, Nam SJ, Kim HJ, Ahn JS, Park YS, Lim HY, Han BK, Yang JH.
Cancer Chemother Pharmacol. 2008 Apr;61(4):569-77. Epub 2007 May 17.
Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer.
Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, Lecocke M, Metivier J, Booser D, Ibrahim N, Valero V, Royce M, Arun B, Whitman G, Ross J, Sneige N, Hortobagyi GN, Pusztai L.
J Clin Oncol. 2004 Jun 15;22(12):2284-93. Epub 2004 May 10.
A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer.
Stearns V, Singh B, Tsangaris T, Crawford JG, Novielli A, Ellis MJ, Isaacs C, Pennanen M, Tibery C, Farhad A, Slack R, Hayes DF.
Clin Cancer Res. 2003 Jan;9(1):124-33.
Is drug-induced toxicity a good predictor of response to neo-adjuvant chemotherapy in patients with breast cancer?--a prospective clinical study.
Chintamani, Singhal V, Singh JP, Lyall A, Saxena S, Bansal A.
BMC Cancer. 2004 Aug 13;4:48.
Clinicopathological features of tumors as predictors of the efficacy of primary neoadjuvant chemotherapy for operable breast cancer.
Shien T, Akashi-Tanaka S, Miyakawa K, Hojo T, Shimizu C, Seki K, Ando M, Kohno T, Taira N, Doihara H, Katsumata N, Fujiwara Y, Kinoshita T.
World J Surg. 2009 Jan;33(1):44-51.
HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination.
Tiezzi DG, Andrade JM, Ribeiro-Silva A, Zola FE, Marana HR, Tiezzi MG.
BMC Cancer. 2007 Feb 26;7:36.
Neoadjuvant chemotherapy for locally advanced breast cancer results in alterations in preoperative tumor marker status.
Piper GL, Patel NA, Patel JA, Malay MB, Julian TB.
Am Surg. 2004 Dec;70(12):1103-6.
Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer.
Hannemann J, Oosterkamp HM, Bosch CA, Velds A, Wessels LF, Loo C, Rutgers EJ, Rodenhuis S, van de Vijver MJ.
J Clin Oncol. 2005 May 20;23(15):3331-42.
A pilot study of neoadjuvant paclitaxel and radiation with correlative molecular studies in stage II/III breast cancer.
Chakravarthy A, Nicholson B, Kelley M, Beauchamp D, Johnson D, Frexes-Steed M, Simpson J, Shyr Y, Pietenpol J.
Clin Breast Cancer. 2000 Apr;1(1):68-71.
Serum levels of tumor necrosis factor alpha correlate with response to neoadjuvant chemotherapy in locally advanced breast cancer.
Berberoglu U, Yildirim E, Celen O.
Int J Biol Markers. 2004 Apr-Jun;19(2):130-4.
Clinical and pathological predictors of the response to neoadjuvant anthracycline chemotherapy in locally advanced breast cancer.
Fernández-Sánchez M, Gamboa-Dominguez A, Uribe N, García-Ulloa AC, Flores-Estrada D, Candelaria M, Arrieta O.
Med Oncol. 2006;23(2):171-83.
Concurrent chemo-radiotherapy following neoadjuvant chemotherapy in locally advanced breast cancer.
Alvarado-Miranda A, Arrieta O, Gamboa-Vignolle C, Saavedra-Perez D, Morales-Barrera R, Bargallo-Rocha E, Zinser-Sierra J, Perez-Sanchez V, Ramirez-Ugalde T, Lara-Medina F.
Radiat Oncol. 2009 Jul 11;4:24.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on